Next Article in Journal
Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
Next Article in Special Issue
Combinatory Treatment with miR-7-5p and Drug-Loaded Cubosomes Effectively Impairs Cancer Cells
Previous Article in Journal
Viburnum opulus L. Juice Phenolic Compounds Influence Osteogenic Differentiation in Human Osteosarcoma Saos-2 Cells
Previous Article in Special Issue
Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?
Review

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma

1
Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy
2
Laboratory of Signal Transduction, IRCCS-Fondazione Santa Lucia, 00179 Rome, Italy
3
Institute of Molecular Biology and Pathology, National Research Council (CNR), 00185 Rome, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(14), 4910; https://doi.org/10.3390/ijms21144910
Received: 15 June 2020 / Revised: 7 July 2020 / Accepted: 9 July 2020 / Published: 11 July 2020
Glioblastoma multiforme (GBM) is a severe brain tumor whose ability to mutate and adapt to therapies is at the base for the extremely poor survival rate of patients. Despite multiple efforts to develop alternative forms of treatment, advances have been disappointing and GBM remains an arduous tumor to treat. One of the leading causes for its strong resistance is the innate upregulation of DNA repair mechanisms. Since standard therapy consists of a combinatory use of ionizing radiation and alkylating drugs, which both damage DNA, targeting the DNA damage response (DDR) is proving to be a beneficial strategy to sensitize tumor cells to treatment. In this review, we will discuss how recent progress in the availability of the DDR kinase inhibitors will be key for future therapy development. Further, we will examine the principal existing DDR inhibitors, with special focus on those currently in use for GBM clinical trials. View Full-Text
Keywords: DNA damage response; glioblastoma; DDR inhibitors DNA damage response; glioblastoma; DDR inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Ferri, A.; Stagni, V.; Barilà, D. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. Int. J. Mol. Sci. 2020, 21, 4910. https://doi.org/10.3390/ijms21144910

AMA Style

Ferri A, Stagni V, Barilà D. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. International Journal of Molecular Sciences. 2020; 21(14):4910. https://doi.org/10.3390/ijms21144910

Chicago/Turabian Style

Ferri, Alessandra, Venturina Stagni, and Daniela Barilà. 2020. "Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma" International Journal of Molecular Sciences 21, no. 14: 4910. https://doi.org/10.3390/ijms21144910

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop